Want to see MOLN full AI Analyst Report?
MOLN Stock Chart & Stats
$4.45
$0.11(2.96%)
At close: 4:00 PM EDT
$4.45
$0.11(2.96%)
Day’s Range― - ―
52-Week Range$3.52 - $5.36
Previous Close$3.97
Volume641.00
Average Volume (3M)1.45K
Market Cap
$151.54M
Enterprise Value$67.80M
Total Cash (Recent Filing)$67.69M
Total Debt (Recent Filing)$3.03M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Mar 18, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.35
Shares Outstanding40,374,640
10 Day Avg. Volume1,978
30 Day Avg. Volume1,445
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)1.60
Price to Sales (P/S)0.00
P/FCF Ratio-2.48
Enterprise Value/Market Cap0.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-29.55
Enterprise Value/Ebitda-1.23
Forecast
1Y Price Target
$10.00Price Target Upside124.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.73
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash RunwayThe reported cash balance and expected funding runway provide Molecular Partners with time to advance several clinical programs without an immediate financing requirement. This supports sustained development activity and gives management more flexibility to reach meaningful clinical milestones.
Pipeline AdvancementMultiple programs are moving through clinical or IND-enabling stages across radiopharmaceuticals and immune-cell engagers. This broadens the company’s potential sources of future value and reduces reliance on any single early-stage candidate succeeding.
Low LeverageConservative leverage limits fixed financial obligations while the company absorbs development losses and funds clinical work. Compared with a highly indebted biotech, this balance-sheet structure preserves greater flexibility for partnerships, research investment, and future capital allocation.
Bears Say
Unstable Revenue BaseThe absence of consistent recent revenue shows that Molecular Partners does not yet have a dependable commercial income stream. Results therefore remain exposed to the timing and success of licensing transactions, milestones, or other non-recurring sources of revenue.
Persistent Cash BurnOngoing negative operating and free cash flow means the business is not currently self-funding its research and clinical activities. Continued outflows can reduce financial resources over time and may eventually require additional partnering, financing, or spending controls.
Development-stage Earnings RiskMolecular Partners remains dependent on advancing development programs rather than recurring product sales, leaving earnings tied to uncertain clinical progress and partnership economics. Sustained losses can constrain investment capacity and make future financial performance uneven.
Molecular Partners News
MOLN FAQ
What was Molecular Partners’s price range in the past 12 months?
Molecular Partners lowest stock price was $3.52 and its highest was $5.36 in the past 12 months.
What is Molecular Partners’s market cap?
Molecular Partners’s market cap is $151.54M.
When is Molecular Partners’s upcoming earnings report date?
Molecular Partners’s upcoming earnings report date is Mar 18, 2027 which is in 151 days.
How were Molecular Partners’s earnings last quarter?
Molecular Partners released its earnings results on Aug 25, 2026. The company reported -$0.434 earnings per share for the quarter, missing the consensus estimate of -$0.433 by -$0.001.
Is Molecular Partners overvalued?
According to Wall Street analysts Molecular Partners’s price is currently Undervalued.
Does Molecular Partners pay dividends?
Molecular Partners does not currently pay dividends.
What is Molecular Partners’s EPS estimate?
Molecular Partners’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Molecular Partners have?
Molecular Partners has 40,374,640 shares outstanding.
What happened to Molecular Partners’s price movement after its last earnings report?
Molecular Partners reported an EPS of -$0.434 in its last earnings report, missing expectations of -$0.433. Following the earnings report the stock price went down -0.455%.
Which hedge fund is a major shareholder of Molecular Partners?
Currently, no hedge funds are holding shares in MOLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Molecular Partners
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
MOLN Stock 12 Month Forecast
Average Price Target
$10.00
▲(124.72% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
8.86% Other Institutional Investors
91.14% Public Companies and
Individual Investors